Restore Mind Medicine
Flawed Approach for Phase llb
Even if a Phase Ilb were needed, we believe Mind Med's approach is
flawed and will result in further issues.
MindMed should have negotiated for a pivotal Phase IIb trial, to save time and money.
MindMed's Phase IIb has a flawed dosing regimen as it tests a single dose of MM-120 rather than
two doses, which was successful in multiple randomized Phase II trials.
In other words, Barrow is taking a significant risk by changing the dosing schedule that has been
successful in Phase II randomized trials without data to support it has higher efficacy.
The flawed Phase Ilb will result in a flawed Phase III as Barrow states
that the Phase III will use one dose.
Despite Barrow's assertion to the contrary, just because two doses are highly effective, there is no
evidence that one dose will have similar efficacy.
Source: Clinicaltrials.gov, MindMed Earnings Call.
34View entire presentation